Alnylam Pharmaceuticals (ALNY) TD Cowen 46th Annual Health Care Conference summary

Revenue growth and market dynamics

• AMVUTTRA's revenue growth is driven by increasing treatment rates in an underdiagnosed, undertreated disease, with current treatment rates at 20%-25% and historical annual growth of 40%.

• Market access for AMVUTTRA is strong, with over 90% of patients having first-line access and minimal payer restrictions or step edits, especially in Medicare segments.

• The focus remains on expanding first-line market share, currently in the mid to high twenties percent, with no set internal target but strong positioning.

• Revenue guidance for the franchise is $4.4–$4.7 billion by 2026, representing 83% growth at the midpoint, and a 25% total revenue CAGR through 2030.

• Competitive landscape is evolving, with new entrants expected to expand the market rather than erode share, and AMVUTTRA maintaining a leadership position in new patient starts.

Pipeline development and innovation

• Next-generation TTR therapy, nucresiran, is in early phase trials with twice-yearly dosing and deeper knockdown, aiming for a 2028 launch in polyneuropathy and 2030 in cardiomyopathy.

• Nucresiran is expected to consolidate and grow the TTR franchise, improve margins, and extend growth beyond 2030.

• The pipeline includes zilebesiran for hypertension (in phase III), REV-14 for diabetes (phase II proof of concept by year-end), and a plasminogen-targeting agent for bleeding disorders (phase II data by year-end).

• Huntington's disease program targets exon 1 with RNAi, aiming for 40%-50% knockdown and phase I data by year-end.

• Pipeline strategy emphasizes both internal innovation and selective external opportunities, with a focus on expanding into new tissues and therapeutic areas.

Financial strategy and long-term outlook

• Operating margin guidance is set at 30% through 2030, with 30% of revenues reinvested in R&D to support pipeline growth and diversification.

• The company aims to be in 10 tissues by 2030 and have at least two new therapies beyond TTR in or near market.

• External innovation and business development will be included within the 30% R&D reinvestment rate, focusing on early-stage assets and technology enhancements.

• Commercial synergies and franchise expansion are considered in asset selection, with a willingness to invest in SG&A for long-term growth.

• The financial plan does not rely on near-term revenue acquisitions, prioritizing organic and early-stage pipeline investments.